CA3184128A1 - Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes - Google Patents
Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomesInfo
- Publication number
- CA3184128A1 CA3184128A1 CA3184128A CA3184128A CA3184128A1 CA 3184128 A1 CA3184128 A1 CA 3184128A1 CA 3184128 A CA3184128 A CA 3184128A CA 3184128 A CA3184128 A CA 3184128A CA 3184128 A1 CA3184128 A1 CA 3184128A1
- Authority
- CA
- Canada
- Prior art keywords
- methylation
- subject
- infection
- covid
- classifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042669P | 2020-06-23 | 2020-06-23 | |
| US63/042,669 | 2020-06-23 | ||
| PCT/US2021/038763 WO2021262894A1 (en) | 2020-06-23 | 2021-06-23 | Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3184128A1 true CA3184128A1 (en) | 2021-12-30 |
Family
ID=79281779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3184128A Pending CA3184128A1 (en) | 2020-06-23 | 2021-06-23 | Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240093318A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4168593A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023532444A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230038486A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096920A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021297245A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026509A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3184128A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000105A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262894A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230158101A (ko) * | 2021-03-18 | 2023-11-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 수술 위험도 점수를 생성하는 시스템 및 방법 및 그 용도 |
| EP4303326A1 (fr) * | 2022-07-06 | 2024-01-10 | Biomérieux | Determination du risque de deces d'un sujet infecte par un virus respiratoire par mesure du niveau d'expression du gene oas2 |
| WO2024008955A1 (en) * | 2022-07-08 | 2024-01-11 | Age Labs As | Method of screening for severe covid-19 susceptibility |
| CN117587124A (zh) * | 2022-08-16 | 2024-02-23 | 武汉艾米森生命科技有限公司 | 诊断胰腺癌的检测试剂和试剂盒及应用 |
| EP4484575A1 (de) * | 2023-06-30 | 2025-01-01 | Cerascreen GmbH | Markersequenzen zur diagnose und therapiesteuerung von patienten mit testosteron-defizienz |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| EP2298900A1 (en) | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| WO2001041782A2 (en) | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| JP2004500405A (ja) | 2000-03-29 | 2004-01-08 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア | 抗原の免疫原性を増強するための組成物および方法 |
| AU2001276371A1 (en) * | 2000-06-30 | 2002-01-14 | Epigenomics Ag | Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| WO2003102168A1 (en) | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Attenuated listeria spp. and methods for using the same |
| AU2004204751A1 (en) | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| ATE552843T1 (de) | 2003-02-06 | 2012-04-15 | Aduro Biotech | Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| US7665238B2 (en) | 2006-04-03 | 2010-02-23 | S.C. Johnson & Son, Inc. | Air freshener with holder |
| DK2148923T3 (da) | 2007-05-18 | 2012-12-03 | Medimmune Llc | Konservering af biologisk aktive materialer med frysetørret skum |
| JP5985397B2 (ja) | 2009-11-11 | 2016-09-06 | アドバクシス インコーポレイテッド | 組換えリステリア株およびそれを含む免疫原性組成物 |
| WO2011082436A1 (en) * | 2010-01-04 | 2011-07-07 | Lineagen, Inc. | Dna methylation biomarkers of lung function |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| AU2013370210B2 (en) | 2012-12-27 | 2018-06-14 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| CN106794235A (zh) | 2014-07-18 | 2017-05-31 | 阿德瓦希斯公司 | 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物 |
| WO2016011357A1 (en) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| BR112019018272A2 (pt) * | 2017-03-02 | 2020-07-28 | Youhealth Oncotech, Limited | marcadores metilação para diagnosticar hepatocelular carcinoma e câncer |
| CA3055895A1 (en) * | 2017-03-10 | 2018-09-13 | Self-Screen B.V. | A methylation classifier for detection of hpv-induced invasive cancers, nonhpv- induced gynaecological and anogenital cancers and their high-grade precursor lesions |
-
2021
- 2021-06-23 AU AU2021297245A patent/AU2021297245A1/en active Pending
- 2021-06-23 MX MX2023000105A patent/MX2023000105A/es unknown
- 2021-06-23 WO PCT/US2021/038763 patent/WO2021262894A1/en not_active Ceased
- 2021-06-23 EP EP21828082.4A patent/EP4168593A4/en active Pending
- 2021-06-23 CN CN202180044432.0A patent/CN116096920A/zh active Pending
- 2021-06-23 CA CA3184128A patent/CA3184128A1/en active Pending
- 2021-06-23 BR BR112022026509A patent/BR112022026509A2/pt unknown
- 2021-06-23 KR KR1020237001814A patent/KR20230038486A/ko active Pending
- 2021-06-23 US US18/002,979 patent/US20240093318A1/en active Pending
- 2021-06-23 JP JP2022579814A patent/JP2023532444A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4168593A4 (en) | 2024-11-27 |
| JP2023532444A (ja) | 2023-07-28 |
| KR20230038486A (ko) | 2023-03-20 |
| CN116096920A (zh) | 2023-05-09 |
| AU2021297245A1 (en) | 2023-02-02 |
| WO2021262894A1 (en) | 2021-12-30 |
| MX2023000105A (es) | 2023-04-25 |
| US20240093318A1 (en) | 2024-03-21 |
| EP4168593A1 (en) | 2023-04-26 |
| BR112022026509A2 (pt) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024200059B2 (en) | Methods and systems for analysis of organ transplantation | |
| US20240093318A1 (en) | Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes | |
| US20240282449A1 (en) | Methods and systems for machine learning analysis of inflammatory skin diseases | |
| US20220399116A1 (en) | Systems and methods for assessing a bacterial or viral status of a sample | |
| AU2023226757A1 (en) | Methods for diagnosis of bacterial and viral infections | |
| US11257569B1 (en) | Methods of assessing risk of developing a severe response to coronavirus infection | |
| JP2025515307A (ja) | 炎症を治療するためのトランスクリプトーム解析 | |
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| Duffy | Understanding immune variation for improved translational medicine | |
| US20250391505A1 (en) | Methods and Systems for Machine Learning Analysis of Lupus Nephritis | |
| US20260117297A1 (en) | Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases | |
| US20170088902A1 (en) | Expression profiling for cancers treated with anti-angiogenic therapy | |
| US20220205042A1 (en) | Molecular Signatures for Distinguishing Liver Transplant Rejections or Injuries | |
| CN106119406B (zh) | 多发性肉芽肿血管炎及微小动脉炎的基因分型诊断试剂盒及使用方法 | |
| EP3825418A2 (en) | Molecular signatures for distinguishing liver transplant rejections or injuries | |
| WO2024102200A9 (en) | Methods and systems for evaluation of lupus based on ancestry-associated molecular pathways | |
| EP4413164A1 (en) | Screening method for rheumatoid arthritis | |
| US20230340569A1 (en) | Methods for detecting primary immunodeficiency | |
| US11104951B2 (en) | Molecular signatures for distinguishing liver transplant rejections or injuries | |
| Deng et al. | A novel Bayesian framework for harmonizing information across tissues and studies to increase cell type deconvolution accuracy | |
| Cathomas et al. | Two distinct immunopathological profiles in autopsy lungs of COVID-19 | |
| Du | Diagnosing and predicting clinical outcomes based on computational methods for immune microenvironment patterns: two examples | |
| Liang et al. | Study on the Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus Using Integrated Bioinformatics Method | |
| Casanova | Molecular Strategies to Distinguish Key Subphenotypes in Sarcoidosis | |
| Li et al. | A Unique Population of Lipid-Associated Macrophages in Cerebrospinal Fluid: Implications for NSCLC Leptomeningeal Metastases Development and Osimertinib Resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250616 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250623 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250627 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250903 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250903 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250903 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250903 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250903 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260602 |